Global RNA-Targeted Small Molecule Drugs Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report ID: GIR2208020025 | Category: Service & Software | Pages: 110 | Format: PDF | Published Date: September 01,2022

Request Sample Enquiry before buying Ask For Discount

Single User-$3480.00 Multi User-$5220.00

Report Description
View Table of Contents

Report Summary

The RNA-Targeted Small Molecule Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 and Russia-Ukraine War influence, the global RNA-Targeted Small Molecule Drugs market size was valued at USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period.
The RNA-Targeted Small Molecule Drugs market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the global market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.
SMA occupied for % of the RNA-Targeted Small Molecule Drugs global market in 2021, and it is projected to value USD million by 2028, growing at a % CAGR in next six years. In terms of product type, mRNA Translation Regulation segment is altered to a % CAGR between 2022 and 2028.
Global key companies of RNA-Targeted Small Molecule Drugs include Roche, Novartis, PTC Therapeutics, Biogen and Accent Therapeutics, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Key Features of This Report:
This report provides in-depth analysis of the global RNA-Targeted Small Molecule Drugs market, and provides market size and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year.
Main RNA-Targeted Small Molecule Drugs companies’ industry ranking, revenue, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This reports profiles key players in the global RNA-Targeted Small Molecule Drugs market based on the following parameters – headquarters, products portfolio, RNA-Targeted Small Molecule Drugs revenue, and gross margin, recent developments.
Evaluation and forecast the RNA-Targeted Small Molecule Drugs market size, projected growth trends, and corresponding market share analysis by type, by application, and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market segmentation
RNA-Targeted Small Molecule Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of revenue. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type (2017-2028; USD Million)
    mRNA Translation Regulation
    RNA Splicing Modification
    Direct RNA Targeting
    Indirect RNA Targeting - Epitranscriptomics
Market segment by Application (2017-2028; USD Million)
    SMA
    Oncology
    Lung Fibrosis
    Huntington's Disease
    Others
The key market players for global RNA-Targeted Small Molecule Drugs market are listed below:
    Roche
    Novartis
    PTC Therapeutics
    Biogen
    Accent Therapeutics
    Anima Biotech
    Arrakis Pharmaceuticals
    Epics Therapeutics
    Expansion Therapeutics
    Gotham Therapeutics
    H3 Biomedicine
    Ribometrix
    Skyhawk Therapeutics
    STORM Therapeutics
    Twentyeight-Seven Therapeutics
Region Segment (2017-2028; USD Million)
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Australia)
    South America (Brazil, Argentina, Colombia and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe RNA-Targeted Small Molecule Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of RNA-Targeted Small Molecule Drugs, with revenue, gross margin and global market share of RNA-Targeted Small Molecule Drugs from 2019 to 2022.
Chapter 3, the RNA-Targeted Small Molecule Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and RNA-Targeted Small Molecule Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe RNA-Targeted Small Molecule Drugs research findings and conclusion, appendix and data source.

1 Market Overview
    1.1 Product Overview and Scope of RNA-Targeted Small Molecule Drugs
    1.2 Classification of RNA-Targeted Small Molecule Drugs by Type
        1.2.1 Overview: Global RNA-Targeted Small Molecule Drugs Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type in 2021
        1.2.3 mRNA Translation Regulation
        1.2.4 RNA Splicing Modification
        1.2.5 Direct RNA Targeting
        1.2.6 Indirect RNA Targeting - Epitranscriptomics
    1.3 Global RNA-Targeted Small Molecule Drugs Market by Application
        1.3.1 Overview: Global RNA-Targeted Small Molecule Drugs Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 SMA
        1.3.3 Oncology
        1.3.4 Lung Fibrosis
        1.3.5 Huntington's Disease
        1.3.6 Others
    1.4 Global RNA-Targeted Small Molecule Drugs Market Size & Forecast
    1.5 Global RNA-Targeted Small Molecule Drugs Market Size and Forecast by Region
        1.5.1 Global RNA-Targeted Small Molecule Drugs Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global RNA-Targeted Small Molecule Drugs Market Size by Region, (2017-2022)
        1.5.3 North America RNA-Targeted Small Molecule Drugs Market Size and Prospect (2017-2028)
        1.5.4 Europe RNA-Targeted Small Molecule Drugs Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size and Prospect (2017-2028)
        1.5.6 South America RNA-Targeted Small Molecule Drugs Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 RNA-Targeted Small Molecule Drugs Market Drivers
        1.6.2 RNA-Targeted Small Molecule Drugs Market Restraints
        1.6.3 RNA-Targeted Small Molecule Drugs Trends Analysis
2 Company Profiles
    2.1 Roche
        2.1.1 Roche Details
        2.1.2 Roche Major Business
        2.1.3 Roche RNA-Targeted Small Molecule Drugs Product and Solutions
        2.1.4 Roche RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Roche Recent Developments and Future Plans
    2.2 Novartis
        2.2.1 Novartis Details
        2.2.2 Novartis Major Business
        2.2.3 Novartis RNA-Targeted Small Molecule Drugs Product and Solutions
        2.2.4 Novartis RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Novartis Recent Developments and Future Plans
    2.3 PTC Therapeutics
        2.3.1 PTC Therapeutics Details
        2.3.2 PTC Therapeutics Major Business
        2.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.3.4 PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 PTC Therapeutics Recent Developments and Future Plans
    2.4 Biogen
        2.4.1 Biogen Details
        2.4.2 Biogen Major Business
        2.4.3 Biogen RNA-Targeted Small Molecule Drugs Product and Solutions
        2.4.4 Biogen RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Biogen Recent Developments and Future Plans
    2.5 Accent Therapeutics
        2.5.1 Accent Therapeutics Details
        2.5.2 Accent Therapeutics Major Business
        2.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.5.4 Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Accent Therapeutics Recent Developments and Future Plans
    2.6 Anima Biotech
        2.6.1 Anima Biotech Details
        2.6.2 Anima Biotech Major Business
        2.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Product and Solutions
        2.6.4 Anima Biotech RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Anima Biotech Recent Developments and Future Plans
    2.7 Arrakis Pharmaceuticals
        2.7.1 Arrakis Pharmaceuticals Details
        2.7.2 Arrakis Pharmaceuticals Major Business
        2.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product and Solutions
        2.7.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Arrakis Pharmaceuticals Recent Developments and Future Plans
    2.8 Epics Therapeutics
        2.8.1 Epics Therapeutics Details
        2.8.2 Epics Therapeutics Major Business
        2.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.8.4 Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Epics Therapeutics Recent Developments and Future Plans
    2.9 Expansion Therapeutics
        2.9.1 Expansion Therapeutics Details
        2.9.2 Expansion Therapeutics Major Business
        2.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.9.4 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Expansion Therapeutics Recent Developments and Future Plans
    2.10 Gotham Therapeutics 
        2.10.1 Gotham Therapeutics Details
        2.10.2 Gotham Therapeutics Major Business
        2.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.10.4 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Gotham Therapeutics Recent Developments and Future Plans
    2.11 H3 Biomedicine
        2.11.1 H3 Biomedicine Details
        2.11.2 H3 Biomedicine Major Business
        2.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product and Solutions
        2.11.4 H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 H3 Biomedicine Recent Developments and Future Plans
    2.12 Ribometrix
        2.12.1 Ribometrix Details
        2.12.2 Ribometrix Major Business
        2.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Product and Solutions
        2.12.4 Ribometrix RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Ribometrix Recent Developments and Future Plans
    2.13 Skyhawk Therapeutics
        2.13.1 Skyhawk Therapeutics Details
        2.13.2 Skyhawk Therapeutics Major Business
        2.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.13.4 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.13.5 Skyhawk Therapeutics Recent Developments and Future Plans
    2.14 STORM Therapeutics
        2.14.1 STORM Therapeutics Details
        2.14.2 STORM Therapeutics Major Business
        2.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.14.4 STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.14.5 STORM Therapeutics Recent Developments and Future Plans
    2.15 Twentyeight-Seven Therapeutics
        2.15.1 Twentyeight-Seven Therapeutics Details
        2.15.2 Twentyeight-Seven Therapeutics Major Business
        2.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product and Solutions
        2.15.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.15.5 Twentyeight-Seven Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global RNA-Targeted Small Molecule Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 RNA-Targeted Small Molecule Drugs Players Market Share in 2021
        3.2.2 Top 10 RNA-Targeted Small Molecule Drugs Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 RNA-Targeted Small Molecule Drugs Players Head Office, Products and Services Provided
    3.4 RNA-Targeted Small Molecule Drugs Mergers & Acquisitions
    3.5 RNA-Targeted Small Molecule Drugs New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global RNA-Targeted Small Molecule Drugs Revenue and Market Share by Type (2017-2022)
    4.2 Global RNA-Targeted Small Molecule Drugs Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
    5.1 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2017-2022)
    5.2 Global RNA-Targeted Small Molecule Drugs Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
    6.1 North America RNA-Targeted Small Molecule Drugs Revenue by Type (2017-2028)
    6.2 North America RNA-Targeted Small Molecule Drugs Revenue by Application (2017-2028)
    6.3 North America RNA-Targeted Small Molecule Drugs Market Size by Country
        6.3.1 North America RNA-Targeted Small Molecule Drugs Revenue by Country (2017-2028)
        6.3.2 United States RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        6.3.3 Canada RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        6.3.4 Mexico RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
    7.1 Europe RNA-Targeted Small Molecule Drugs Revenue by Type (2017-2028)
    7.2 Europe RNA-Targeted Small Molecule Drugs Revenue by Application (2017-2028)
    7.3 Europe RNA-Targeted Small Molecule Drugs Market Size by Country
        7.3.1 Europe RNA-Targeted Small Molecule Drugs Revenue by Country (2017-2028)
        7.3.2 Germany RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        7.3.3 France RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        7.3.5 Russia RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        7.3.6 Italy RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Revenue by Type (2017-2028)
    8.2 Asia-Pacific RNA-Targeted Small Molecule Drugs Revenue by Application (2017-2028)
    8.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region
        8.3.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Revenue by Region (2017-2028)
        8.3.2 China RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        8.3.3 Japan RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        8.3.4 South Korea RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        8.3.5 India RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        8.3.7 Australia RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
    9.1 South America RNA-Targeted Small Molecule Drugs Revenue by Type (2017-2028)
    9.2 South America RNA-Targeted Small Molecule Drugs Revenue by Application (2017-2028)
    9.3 South America RNA-Targeted Small Molecule Drugs Market Size by Country
        9.3.1 South America RNA-Targeted Small Molecule Drugs Revenue by Country (2017-2028)
        9.3.2 Brazil RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        9.3.3 Argentina RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Revenue by Type (2017-2028)
    10.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Revenue by Application (2017-2028)
    10.3 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country
        10.3.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Revenue by Country (2017-2028)
        10.3.2 Turkey RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
        10.3.4 UAE RNA-Targeted Small Molecule Drugs Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global RNA-Targeted Small Molecule Drugs Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?